The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion. U.S. Health and Human Services (HHS) Secretary Xavier Becerra late yesterday afternoon announced the Biden administration’s revisions to changes the Trump administration made to HRSA in January during its last days in power. The prior administration’s changes have been on hold since they were announced. In late July, HRSA said the reorganization remained under review.